Monica Michele Carrozzo McSherry: Converging Pathways Between Homocysteine and Cholesterol in Cardiovascular Risk
Monica Michele Carrozzo McSherry, Registered Nutritional Therapist at Healthmatters Health Store, Freelance Writer at Dulwich Nutrition, shared a post on LinkedIn:
“Homocysteine (Hcy), a sulfur-containing amino acid derived from methionine metabolism, is remethylated to methionine via folate and vitamin B12 or transsulfurated to cystathionine via vitamin B6.
Elevated plasma Hcy, or hyperhomocysteinemia, is a recognized risk factor for atherosclerosis, primarily through endothelial dysfunction, oxidative stress, and inflammation.
Hcy promotes reactive oxygen species formation, reduces nitric oxide bioavailability, and stimulates pro-inflammatory pathways, accelerating vascular injury.
Cholesterol, particularly LDL-C, drives atherogenesis through subendothelial deposition, oxidation, and foam cell formation, whereas HDL-C facilitates reverse cholesterol transport and vascular protection.
Evidence indicates that hyperhomocysteinemia interacts with lipid metabolism by increasing LDL oxidation, impairing HDL function, and modulating hepatic cholesterol synthesis.
Oxidized LDL generated under elevated Hcy conditions is highly atherogenic, while inhibition of HDL-associated paraoxonase-1 reduces antioxidant defense, compounding vascular risk.
Genetic variants affecting homocysteine metabolism, such as MTHFR C677T, associate with elevated Hcy and altered lipid profiles, highlighting a combined genetic predisposition to cardiovascular disease.
Epidemiological data suggest additive risk when hyperhomocysteinemia coexists with dyslipidemia.
While B-vitamin supplementation lowers Hcy levels, effects on lipid profiles and cardiovascular outcomes are inconsistent, reflecting complex interactions involving oxidative stress, endothelial repair, and lipid oxidation.
In summary, homocysteine and cholesterol are intertwined modulators of cardiovascular risk.
Hyperhomocysteinemia exacerbates LDL oxidation and HDL dysfunction, potentiating atherogenesis.
Beyond lipid-lowering therapies, nutritional strategies targeting Hcy through folate, B12, and B6 may provide complementary cardiovascular protection, particularly in genetically susceptible populations.
Future research should clarify the mechanistic crosstalk and therapeutic implications of the homocysteine-cholesterol axis.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy